Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial
Nom du journal : J Clin Oncol
Année : 2009
Volume : 27
Page de départ : 3969
Page de fin : 3974